Harnessing M1-Polarized Macrophage-Derived Extracellular Vesicles and Artificial Nanovesicles for Targeted Cancer Drug Delivery
Cells · 27.05.2026 · 15 (11) · 987
DOI: 10.3390/cells15110987 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 27.05.2026. Verfasst von Prakash Gangadaran und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea. Hauptthemen laut MEDLINE: Extracellular Vesicles, Macrophages, Drug Delivery Systems, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 188 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Basic Science Research Program, Korea government.
Abstract (Originalsprache)
Macrophage-derived extracellular vesicles (EVs) have emerged as promising biomimetic platforms for targeted cancer drug delivery due to their biocompatibility, immune-modulatory properties, and tumor-homing capabilities. Among macrophage subtypes, M1-polarized macrophages exhibit potent anti-tumor functions characterized by pro-inflammatory cytokine secretion, improved antigen presentation, and the ability to remodel the tumor microenvironment (TME). Utilizing these properties, M1-polarized macrophage-derived EVs serve as cell-free therapeutic systems capable of delivering bioactive cargo while simultaneously promoting anti-tumor immune responses. However, the clinical application of natural EVs is limited by low yield, heterogeneity, and challenges in large-scale production. Artificial nanovesicles (ANVs) have been developed to address these limitations, offering improved scalability, compositional control, and reproducibility. This review provides an overview of macrophage differentiation and polarization, with a focus on the immunological profile and anti-tumor mechanisms of M1-polarized macrophages. It further discusses current methodologies for EV isolation and ANV generation, along with cargo loading strategies that balance encapsulation efficiency and vesicle stability. In addition, this review also emphasizes their targeting approaches, cellular uptake pathways, and the intracellular trafficking mechanisms that influence delivery efficiency and therapeutic outcomes. Key challenges, including standardization, biological barriers, and functional consistency, are critically evaluated. Emerging strategies that integrate vesicle engineering with personalized medicine underscore the potential of these systems to advance precision oncology.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
- Cardiovascular Research Institute, Kyungpook National University, Daegu 41944, Republic of Korea.
- Amity Institute of Biotechnology, Amity University Uttar Pradesh (AUUP), Noida 201313, India.
- BK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, Department of Biomedical Sciences, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
- Department of Nuclear Medicine, Kyungpook National University Hospital, Daegu 41944, Republic of Korea.
- Department of Biotechnology and Microbiology, SRM University, Sonipat 131023, India.
ORCID-Profile: Prakash Gangadaran, Sanjuda Subramaniyan, Ramya Lakshmi Rajendran, Chae Moon Hong, Saurabh Kumar Jha, Shazia Rashid, Byeong-Cheol Ahn
Förderung
- National Research Foundation of Korea
- Basic Science Research Program
- Korea government
Zitieren
APA
Gangadaran, P., Subramaniyan, S., Rajendran, R. L., Hong, C. M., Swati, K., Jha, S. K., Rashid, S., & Ahn, B. C. (2026). Harnessing M1-Polarized Macrophage-Derived Extracellular Vesicles and Artificial Nanovesicles for Targeted Cancer Drug Delivery. Cells, 15(11), 987. https://doi.org/10.3390/cells15110987
Vancouver
Gangadaran P, Subramaniyan S, Rajendran RL, Hong CM, Swati K, Jha SK, et al. Harnessing M1-Polarized Macrophage-Derived Extracellular Vesicles and Artificial Nanovesicles for Targeted Cancer Drug Delivery. Cells. 2026;15(11):987. doi:10.3390/cells15110987
BibTeX
@article{Gangadaran2026,
author = {Gangadaran, Prakash and Subramaniyan, Sanjuda and Rajendran, Ramya Lakshmi and Hong, Chae Moon and Swati, Kumari and Jha, Saurabh Kumar and Rashid, Shazia and Ahn, Byeong-Cheol},
title = {Harnessing M1-Polarized Macrophage-Derived Extracellular Vesicles and Artificial Nanovesicles for Targeted Cancer Drug Delivery},
journal = {Cells},
year = {2026},
volume = {15},
number = {11},
pages = {987},
doi = {10.3390/cells15110987}
}
EUVIMED